Breast Cancer :: EVISTA for Reduction of Invasive Breast Cancer Risk in Postmenopausal Women
Eli Lilly and Company (NYSE: LLY) announced today that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration’s Division of Drug Oncology Products (DDOP) for EVISTA? (raloxifene HCl) for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis and postmenopausal women at high risk for breast cancer.